Author:
Benninghoff Bernd,Birkenmeier Jürgen,Folkman Judah,Hager Ernst Dieter,Hajeck-Lang Brigitte,Irmey György,Kaltofen Sieghart,Klingmüller Martin,Kraft Karin,Matthei Sabine,Melzer Jörg,Miller Winfried,Multhoff Gabriele,Neßelhut Thomas,Oettmeier Ralf,Peters J. Hinrich,Pfeifer Ben,Ramadani Marco,Rauprich Petra,Reich Gerlinde,Reuter Uwe,Sahinbas Hüseyin,Saller Reinhard,Schirrmacher Volker,Schneider Julia,Stoll Günther,Unger Clemens,Wehner Holger
Reference637 articles.
1. Doehn C, Richter A, Hohn M, Jocham D: Multicenter phase-III trial (aTm1/96) of adjuvant autologous tumor cell-lysate vaccine versus no adjuvant treatment in patients with non-metastasized renal cell carcinoma after radical nephrectomy: A 3-year analysis. In ASCO Meeting, AUA, Orlando Florid, 2002
2. Is cancer dangerous to the immune system?;Fuchs;Semin Immunol,1996
3. Dendritic cells and cancer: Prospects for cancer vaccination;Hart,2002
4. Tolerance, danger, and the extended family;Matzinger;Annu Rev Immunol,1994
5. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive;Muderspach;Clin Cancer Res,2000